Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure

Bone

Volumn 43, Issue 6, 2008, Pages 1022-1030

  Sebastian, Ely M ^a   Suva, Larry J ^b   Friedman, Peter A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone; Microarchitecture; Nephrectomy; Parathyroidectomy; PTH receptor; PTH(1 34); PTH(7 34)

Indexed keywords

CALCIUM; CREATININE; MESSENGER RNA; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[7-34]; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEMINERALIZATION; BONE DENSITY; BONE MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE EXPRESSION; HYPERCALCEMIA; KIDNEY FAILURE; MALE; MINERAL METABOLISM; MORNING DOSAGE; NEPHRECTOMY; NONHUMAN; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; RAT; SINGLE DRUG DOSE; TRABECULAR BONE;

ANIMALS; AORTA; BASE SEQUENCE; BONE AND BONES; CALCINOSIS; DNA PRIMERS; KIDNEY; KIDNEY FAILURE; MALE; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, PARATHYROID HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57049155996     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.07.250     Document Type: Article

References (63)

1. Martin K.J., and Gonzalez E.A. Metabolic bone disease in chronic kidney disease. J. Am. Soc. Nephrol. 18 (2007) 875-885
2. Brown A.J. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J. Steroid Biochem. Mol. Biol. 103 (2007) 578-583
3. Goodman W.G. Calcium-sensing receptors. Semin. Nephrol. 24 (2004) 17-24
4. Fukagawa M., Nakanishi S., Fujii H., Hamada Y., and Abe T. Regulation of parathyroid function in chronic kidney disease (CKD). Clin. Exp. Nephrol. 10 (2006) 175-179
5. Slatopolsky E., Brown A., and Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Inter., Suppl. 73 (1999) S14-S19
6. Cozzolino M., Brancaccio D., Gallieni M., Galassi A., Slatopolsky E., and Dusso A. Pathogenesis of parathyroid hyperplasia in renal failure. J. Nephrol. 18 (2005) 5-8
7. Urena P., Kubrusly M., Mannstadt M., Hruby M., Trinh M.M., Silve C., Lacour B., Abou-Samra A.B., Segre G.V., and Drueke T. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int. 45 (1994) 605-611
8. Chen J., Zhang J., and Lin S. Down-regulation of PTH/PTHrP receptor in the kidney of patients with renal impairment. Chin. Med. J. 111 (1998) 24-27
9. Picton M.L., Moore P.R., Mawer E.B., Houghton D., Freemont A.J., Hutchison A.J., Gokal R., and Hoyland J.A. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 58 (2000) 1440-1449
10. Edwards R.M., Contino L.C., Gellai M., and Brooks D.P. Parathyroid hormone-1 receptor down-regulation in kidneys from rats with chronic renal failure. Pharmacology 62 (2001) 243-247
11. Drüeke T.B. Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Pediatr. Nephrol. 10 (1996) 348-350
12. Urena P. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review. Artif. Organs 27 (2003) 759-764
13. Brown A.J., and Slatopolsky E. Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 134-144
14. Harmar A.J. Family-B G-protein-coupled receptors. Genome Biology 2 (2001) 3013.1-3013.10
15. Mannstadt M., Juppner H., and Gardella T.J. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Physiol. 277 (1999) F665-F675
16. 2+-sensing receptor mRNAs along the rat nephron. Am. J. Physiol. 272 (1997) F751-F758
17. Monier-Faugere M.C., Geng Z., Mawad H., Friedler R.M., Gao P., Cantor T.L., and Malluche H.H. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 60 (2001) 1460-1468
18. Coen G., Bonucci E., Ballanti P., Balducci A., Calabria S., Nicolai G.A., Fischer M.S., Lifrieri F., Manni M., Morosetti M., Moscaritolo E., and Sardella D. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am. J. Kidney Dis. 40 (2002) 348-354
19. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barré N., and D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J. Clin. Endocrinol. Metab. 81 (1996) 3923-3929
20. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., Gao P., Cantor T., and D'Amour P. Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur. J. Endocrinol. 147 (2002) 123-131
21. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., Gao P., Cantor T., and Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int. 58 (2000) 753-761
22. Tian J., Smogorzewski M., Kedes L., and Massry S.G. PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. Am. J. Nephrol. 14 (1994) 41-46
23. Sneddon W.B., Syme C.A., Bisello A., Magyar C.E., Weinman E.J., Rochdi M.D., Parent J.L., Abou-Samra A.B., and Friedman P.A. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J. Biol. Chem. 278 (2003) 43787-43796
24. Sneddon W.B., Bisello A., Magyar C.E., Willick G.E., Syme C.A., Galbiati F., and Friedman P.A. Ligand-selective dissociation of activation and internalization of the parathyroid hormone receptor. Conditional efficacy of PTH peptide fragments. Endocrinology 145 (2004) 2815-2823
25. Magyar C.E., Sneddon W.B., Bisello A., and Friedman P.A. PTH(7-34) downregulates the PTH1 receptor by a ubiquitin-sensitive pathway. J. Bone Miner. Res. 19 (2004) 174-175
26. Weinman E.J., Hall R.A., Friedman P.A., Liu-Chen L.Y., and Shenolikar S. The association of NHERF adaptor proteins with G protein-coupled receptors and receptor tyrosine kinases. Annu. Rev. Physiol. 68 (2006) 491-505
27. +exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 417 (2002) 858-861
28. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., and D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142 (2001) 1386-1392
29. Langub M.C., Monier-Faugere M.C., Wang G., Williams J.P., Koszewski N.J., and Malluche H.H. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144 (2003) 1135-1138
30. Perrien D.S., Akel N.S., Dupont-Versteegden E.E., Skinner R.A., Siegel E.R., Suva L.J., and Gaddy D. Aging alters the skeletal response to disuse in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R988-R996
31. Hildebrand T., and Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput. Methods Biomech. Biomed. Engin. 1 (1997) 15-23
32. Bergwitz C., Jusseaume S.A., Luck M.D., Jüppner H., and Gardella T.J. Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J. Biol. Chem. 272 (1997) 28861-28868
33. Pagani F., Francucci C.M., and Moro L. Markers of bone turnover: biochemical and clinical perspectives. J. Endocrinol. Invest. 28 (2005) 8-13
34. Delmas P.D. Biochemical markers of bone turnover. J. Bone Miner. Res. 8 Suppl 2 (1993) S549-S555
35. Cozzolino M., Brancaccio D., Gallieni M., and Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 68 (2005) 429-436
36. Jono S., Shioi A., Ikari Y., and Nishizawa Y. Vascular calcification in chronic kidney disease. J. Bone Miner. Metab. 24 (2006) 176-181
37. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., and Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
38. Friedl G., Turner R.T., Evans G.L., and Dobnig H. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. Journal of Orthopaedic Research 25 (2007) 1454-1464
39. Ahlgren O., and Larsson S.E. The role of the parathyroids for the adaptation to a low calcium intake. 3. The long-term effect of parathyroidectomy on the adaptation to a low calcium intake in adult rats with special reference to plasma calcium, bone tissue and adrenal glands. Acta Pathol. Microbiol. Scand., A 83 (1975) 590-602
40. Skripitz R., and Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J. Bone Jt. Surg. British Volume 83 (2001) 437-440
41. Brossard J.H., Yamamoto L.N., and D'Amour P. Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Sem. Dial. 15 (2002) 196-201
42. D'Amour P., Brossard J.H., Rousseau L., Nguyen-Yamamoto L., Nassif E., Lazure C., Gauthier D., Lavigne J.R., and Zahradnik R.J. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 68 (2005) 998-1007
43. Bank N., Su W.S., and Aynedjian H.S. A micropuncture study of renal phosphate transport in rats with chronic renal failure and secondary hyperparathyroidism. J. Clin. Invest. 61 (1978) 884-894
44. Onyia J.E., Helvering L.M., Gelbert L., Wei T., Huang S., Chen P., Dow E.R., Maran A., Zhang M., Lotinun S., Lin X., Halladay D.L., Miles R.R., Kulkarni N.H., Ambrose E.M., Ma Y.L., Frolik C.A., Sato M., Bryant H.U., and Turner R.T. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell. Biochem. 95 (2005) 403-418
45. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., and Hock J.M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33 (2003) 372-379
46. Rickard D.J., Wang F.L., Rodriguez-Rojas A.M., Wu Z., Trice W.J., Hoffman S.J., Votta B., Stroup G.B., Kumar S., and Nuttall M.E. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39 (2006) 1361-1372
47. Simmons H.A., Pirie C.M., Thompson D.D., and Ke H.Z. Parathyroid hormone (1-34) increased total body bone mass in aged female rats. J. Pharmacol. Exp. Ther. 286 (1998) 341-344
48. Iwasaki-Ishizuka Y., Yamato H., Nii-Kono T., Kurokawa K., and Fukagawa M. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol. Dial. Transplant. 20 (2005) 1904-1911
49. 2. Endocrinology 123 (1988) 2597-2599
50. Gardella T.J., Luck M.D., Jensen G.S., Schipani E., Potts Jr. J.T., and Jüppner H. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137 (1996) 3936-3941
51. Murray T.M., Rao L.G., Divieti P., and Bringhurst F.R. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr. Rev. 26 (2005) 78-113
52. Divieti P., Geller A.I., Suliman G., Juppner H., and Bringhurst F.R. Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 146 (2005) 1863-1870
53. Miller M.A., Chin J., Miller S.C., and Fox J. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23 (1998) 257-266
54. Magnusson P., Sharp C.A., Magnusson M., Risteli J., Davie M.W., and Larsson L. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int. 60 (2001) 257-265
55. Fukagawa M., Kazama J.J., and Shigematsu T. Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases. Am. J. Kidney Dis. 38 (2001) S152-S155
56. Epstein S., Dissanayake I.R., Goodman G.R., Bowman A.R., Zhou H., Ma Y., and Jee W.S. Effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat. Calcif. Tissue Int. 68 (2001) 240-247
57. Ureña P., Mannstadt M., Hruby M., Ferreira A., Schmitt F., Silve C., Ardaillou R., Lacour B., Abou-Samra A.B., Segre G.V., and Drüeke T. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int. 47 (1995) 1797-1805
58. Disthabanchong S., Hassan H., McConkey C.L., Martin K.J., and Gonzalez E.A. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int. 65 (2004) 897-903
59. London G.M., Marchais S.J., Guerin A.P., and Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr. Opin. Nephrol. Hypertens. 14 (2005) 525-531
60. Goodman W.G., London G., Amann K., Block G.A., Giachelli C., Hruska K.A., Ketteler M., Levin A., Massy Z., McCarron D.A., Raggi P., Shanahan C.M., and Yorioka N. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 43 (2004) 572-579
61. Lomashvili K., Garg P., and O'Neill W.C. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int. 69 (2006) 1464-1470
62. Block G.A., and Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. 35 (2000) 1226-1237
63. Iwasaki-Ishizuka Y., Yamato H., Nii-Kono T., Kurokawa K., and Fukagawa M. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol. Dial. Transplant 20 (2005) 1904-1911